Career

Antoni Ribas and Jedd Wolchok selected as 2024 Fellows of the Academy of Immuno-Oncology

A collage photo of Antoni Ribas and Jedd Wolchok

Aug 7, 2024, 17:21

Antoni Ribas and Jedd Wolchok selected as 2024 Fellows of the Academy of Immuno-Oncology

Parker Institute for Cancer Immunotherapy shared on X:

“Congrats to PICI Center Directors Antoni Ribas (UCLA) and Jedd Wolchok (Weill Cornell Medicine) on their selection as 2024 Fellows of the Academy of Immuno-Oncology.

Their work continues to advance cancer immunotherapy, benefiting patients worldwide.”

Additional information.
Source: Parker Institute for Cancer Immunotherapy/X

Antoni Ribas, MD, PhD, is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA). He is also the director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA. His research is focused on laboratory and clinical studies to address primary and acquired resistance to immunotherapy and targeted therapies for melanoma, and in the development of gene-engineered adoptive T cell transfer therapies for cancer.

Jedd D. Wolchok is the Meyer Director of the Sandra and Edward Meyer Cancer Center and a professor of medicine at Weill Cornell Medicine. Previously, he was the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation. He was also the associate director, of the the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. He is renowned for leading the clinical trials that led to the first FDA-approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab.